Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Recce Pharmaceuticals Ltd. (AU:RCE)
ASX:RCE
RESEARCH TOOLSreports
Holding AU:RCE?
Track your performance easily
RCE Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.38 - AU$0.70
Previous CloseAU$0.5
Volume28.69K
Average Volume (3M)157.07K
Market Cap
AU$115.94M
Enterprise ValueAU$104.43M
Total Cash (Recent Filing)AU$11.58M
Total Debt (Recent Filing)AU$74.76K
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Feb 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares OutstandingN/A
10 Day Avg. Volume175,042
30 Day Avg. Volume157,066
Standard Deviation0.23
R-Squared0.05
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Recce Pharmaceuticals Ltd. News
PremiumCompany Announcements
Recce Pharmaceuticals Boosted by $6.75M R&D Rebate
PremiumCompany Announcements
Recce Pharmaceuticals Issues New Options for Growth
PremiumCompany Announcements
Recce Pharmaceuticals Advances Phase 3 Trial in IndonesiaPremiumCompany Announcements
Recce Pharmaceuticals Adopts New Constitution Amid Drug Innovation
PremiumCompany Announcements
Recce Pharmaceuticals Advances with Strategic Meeting Outcome
PremiumCompany Announcements
Recce Pharmaceuticals Gains Momentum with Shareholder SupportPremiumCompany Announcements
Recce Pharmaceuticals Outlines Future Plans Amid Uncertainties
PremiumCompany Announcements
Recce Pharmaceuticals Advances in Promising Skin Infection TrialOptions Prices
Currently, No data available
---
Ownership Overview
RCE FAQ
What was Recce Pharmaceuticals Ltd.’s price range in the past 12 months?
Recce Pharmaceuticals Ltd. lowest share price was AU$0.38 and its highest was AU$0.69 in the past 12 months.
What is Recce Pharmaceuticals Ltd.’s market cap?
Currently, no data Available
When is Recce Pharmaceuticals Ltd.’s upcoming earnings report date?
Recce Pharmaceuticals Ltd.’s upcoming earnings report date is Feb 26, 2025 which is in 97 days.
How were Recce Pharmaceuticals Ltd.’s earnings last quarter?
Recce Pharmaceuticals Ltd. released its earnings results on Aug 30, 2024. The company reported -AU$0.058 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.058.
Is Recce Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Recce Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Recce Pharmaceuticals Ltd. pay dividends?
Recce Pharmaceuticals Ltd. does not currently pay dividends.
What is Recce Pharmaceuticals Ltd.’s EPS estimate?
Recce Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Recce Pharmaceuticals Ltd. have?
Recce Pharmaceuticals Ltd. has 231,871,610 shares outstanding.
What happened to Recce Pharmaceuticals Ltd.’s price movement after its last earnings report?
Recce Pharmaceuticals Ltd. reported an EPS of -AU$0.058 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.167%.
Which hedge fund is a major shareholder of Recce Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:RCE
---
Recce Pharmaceuticals Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:RCE Sentiment 90%
Sector Average 73%
Sector Average 73%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
13.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
149.22%
Trailing 12-Months
Company Description
Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. It operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibiotic drugs to treat the diseases caused by various bacterias namely Sepsis, Helicobacter Pylori, Escherichia coli, Pseudomonas aeruginosa, and others.
---
Technical Analysis
PYC Therapeutics Limited
―
Resonance Health Ltd
―
Race Oncology Ltd.
―
Vita Life Sciences Limited
―
---